Proof of concept trial of 0.01% ibudilast ophthalmic solution for accommodative asthenopia in healthy adult.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Ibudilast (Primary)
- Indications Alcoholism; Allergic conjunctivitis; Amyotrophic lateral sclerosis; Asthma; Brain injuries; Cerebrovascular disorders; Glioblastoma; Globoid cell leukodystrophy; Multiple sclerosis; Opioid abuse; Substance-related disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 23 Apr 2019 Status changed from not yet recruiting to completed.
- 03 Nov 2017 New trial record